GenoScreen
Meet us at the 42nd Annual Congress of the European Society of Mycobacteriology (ESM) from June 26th to 29th in Bologna, Italy.
The program of this 42nd edition has for main topics Covid and Tuberculosis and will address new diagnostic strategies.
Meet us at the 32th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
Meet us at the 32th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) from April 23th to 26th in Lisbon, Portugal.
Meet GenoScreen at the Adebiotech High Throughput Sequencing Applications Webinar
Adebiotech is holding a new edition of its webinar dedicated to the applications of high throughput NGS sequencing on March 10th 2022.
Deeplex® Myc-TB: Pursue the global deployment of the innovative solution for predicting antibiotic resistance in tuberculosis
GenoScreen and ScienceVision announce an agreement to commercialize the Deeplex® Myc-TB test in Malaysia, Myanmar and Brunei.
Deeplex Myc-TB, a breakthrough innovation to effectively fight tuberculosis
Tuberculosis has been a major scourge since antiquity. The fight against this disease requires ever more efficient technologies. GenoScreen, a French biotech company, has recently developed a new weapon for predicting antibiotic resistance in the germs responsible for this disease. This new test, which comes in the form of a kit, quickly and efficiently detects the genetic mutations in the DNA of pathogenic germs and guides doctors in their medical prescriptions. This test is already being implemented in some thirty countries.
A microbial signature in indoor air associated with severe asthma
Press release - Researchers from GenoScreen and the Cardio-Thoracic Research Centre of Bordeaux (Inserm U1045) have demonstrated relationships between microorganisms in indoor air and those in asthmatic patients’ lungs. This work, published in the Journal of Allergy and Clinical Immunology and highlighted by the American Academy of Allergy, Asthma and Immunology (AAAI), also shows a variation in these micro- and mycobiota according to the patients’ inflammatory reaction type (T2 endotype).
NUMBER OF NEW CASES IN CONTACTS OF LEPROSY PATIENTS DECREASES AFTER DOSE OF ANTIBIOTIC
This is confirmed by preliminary results of the PEOPLE study. This study is an opportunity for GenoScreen to apply its "Deeplex® Myc-Lep" sequencing assay for the first time to an international study.
Subcategories
Partners
GenoScreen develops its technologies and know-how in genomics within a dense, well-structured network of partners.
These collaborations co-fund ambitious research programs and jointly develop innovative technologies: an effective and agile strategy that opens up new opportunities for our staff.
Collaborative research - At the heart of international innovation in genomics
GenoScreen is a partner in collaborative research projects that bring together startups, multinationals and public-sector organizations. Our R&D teams provide their knowledge and expertise in the molecular microbiology of isolated agents and complex communities. This allowed our teams to develop our own projects for elaborating innovative products and services.
Our projects are designed to:
- Improve the diagnosis and management of acute/chronic diseases on humans and animals,
- Characterize and monitor microbial biodiversity, with applications in agronomy, agrifood and environment.
The common feature of these projects is the development of molecular tools for the characterization, monitoring and diagnosis of microbial communities. The key objective is to market simple analytical solutions and (ultimately) preventive, corrective or even therapeutic products based on microorganisms.